文献速递慢性肾脏病血液净化与透析

3期或4期慢性肾脏病5年肾脏替代治疗风险预测:模型开发与外部验证

Predicting 5-Year Risk of RRT in Stage 3 or 4 CKD: Development and External Validation.
PubMed 文献 · Clin J Am Soc Nephrol · 2016-12-27

本研究采用回顾性队列设计,在22,460例3/4期慢性肾脏病(CKD)患者中开发5年进展至肾脏替代治疗(RRT)风险的预测模型,并在16,553例患者中进行外部验证。模型包含8个预测因子,开发队列c统计量0.96、R²为79.7%,验证队列c统计量0.95、R²为81.2%,校准良好。以预测风险最高五分位为切点,敏感性为92.2%。

要点

  • 模型纳入年龄、性别、eGFR、血红蛋白、蛋白尿/白蛋白尿、收缩压、降压药使用及糖尿病及其并发症共8个预测因子。
  • 开发队列c统计量0.96、R²为79.7%;外部验证队列c统计量0.95、R²为81.2%,校准良好。
  • 以预测风险最高五分位为切点,敏感性为92.2%。

核心结论

  • 开发了一个实用的预测模型和风险评分,用于预测3期和4期CKD患者5年RRT风险,使用常规初级保健中可获得的变量,可帮助指导转诊肾脏科时机和瘘管放置等重要决策。

研究设计与样本

  • 回顾性队列设计;开发队列为22,460例Kaiser Permanente Northwest成员,3期或4期CKD,基线2002-2008年;验证队列为16,553例Kaiser Permanente Colorado成员,3-4期CKD,基线2006-2008年。

主要发现

  • Northwest队列发生737例事件,观察5年Kaplan-Meier风险为4.72%(95%CI 4.38至5.06);Colorado队列发生360例事件,观察5年Kaplan-Meier风险为2.57%(95%CI 2.30至2.83)。
  • 开发队列模型表现极好,c统计量0.96,R²为79.7%,校准良好;外部验证队列c统计量0.95,R²为81.2%,校准良好。
  • 在外部验证队列中,最高风险五分位的观察风险略低于预测风险。
  • 以预测风险最高五分位为切点,敏感性为92.2%。

关键数值与推荐

  • 最终模型包括八个预测因子:年龄、性别、eGFR、血红蛋白、蛋白尿/白蛋白尿、收缩压、降压药物使用、糖尿病及其并发症。
  • 以预测风险最高五分位为切点,敏感性为92.2%。

临床怎么用

  • 模型使用常规初级保健中通常可获得的变量,可帮助指导转诊肾脏科时机和瘘管放置等重要决策。

局限性

  • 在外部验证队列中,最高风险五分位的观察风险略低于预测风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Only a minority of patients with CKD progress to renal failure. Despite the potential benefits of risk stratification in the CKD population, risk prediction models are not routinely used. Our objective was to develop and externally validate a clinically useful and pragmatic prediction model for the 5-year risk of progression to RRT in stage 3 or 4 CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used a retrospective cohort design. The development cohort consisted of 22,460 Kaiser Permanente Northwest members with stage 3 or 4 CKD (baseline 2002-2008). The validation cohort consisted of 16,553 Kaiser Permanente Colorado members with stage 3-4 CKD (baseline 2006-2008). The final model included eight predictors: age, sex, eGFR, hemoglobin, proteinuria/albuminuria, systolic BP, antihypertensive medication use, and diabetes and its complications. RESULTS: In the Northwest and Colorado cohorts, there were 737 and 360 events, and observed 5-year Kaplan-Meier risks of 4.72% (95% confidence interval [95% CI], 4.38 to 5.06) and 2.57% (95% CI, 2.30 to 2.83), respectively. Our prediction model performed extremely well in the development cohort, with a c-statistic of 0.96, an R2 of 79.7%, and good calibration. We had similarly good performance in the external validation cohort, with a c-statistic of 0.95, R2 of 81.2%, and good calibration. In the external validation cohort, the observed risk was slightly lower than the predicted risk in the highest-risk quintile. Using the top quintile of predicted risk as a cutpoint gave a sensitivity of 92.2%. CONCLUSIONS: We developed a pragmatic prediction model and risk score for predicting the 5-year RRT risk in stage 3 and 4 CKD. This model uses variables that are typically available in routine primary care settings, and can be used to help guide important decisions such as timing of referral to nephrology and fistula placement.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Schroeder EB, Yang X, Thorp ML, et al. Predicting 5-Year Risk of RRT in Stage 3 or 4 CKD: Development and External Validation. Clin J Am Soc Nephrol. 2016. PMID: 28028051. doi:10.2215/CJN.01290216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。